CHMP2B and amyotrophic lateral sclerosis: Genetic screening of TARDBP identified several pathogenic mutations located on the C-terminal region in both familial (with and without FTD) as well as sporadic ALS.[66] The overlap between these two different clinical entities suggests that the diagnostic genetic screening in FTD-ALS should include both FTD-related as well as ALS-related genes including, PGRN, VCP, CHMP2B, SOD1, TDP-43 etc [Figure 4].